1 – 5 of 6
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Effects of baseline symptom burden on treatment response in COPD
(
- Contribution to journal › Article
- 2016
-
Mark
Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies
(
- Contribution to journal › Article
-
Mark
The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
(
- Contribution to journal › Article
-
Mark
Author’s reply
(
- Contribution to journal › Letter
- 2015
-
Mark
Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
(
- Contribution to journal › Article